Genomic Subtypes of AML Determines Sensitivity to NK Cell Cytotoxicity

AML is a very heterogeneous disease and in this MEDtalk, Hanna Duàn, PhD researcher from the Hematology Research Unit at the University of Helsinki, Finland, explains how genomic subtypes of AML can be a way to determine the most suitable treatment for patients.